TY  - JOUR
AU  - Castro-Laria, Luisa
AU  - Argüelles-Arias, Federico
AU  - García-Sánchez, Valle
AU  - Benítez, José Manuel
AU  - Fernández-Pérez, Ramón
AU  - Trapero-Fernández, Ana María
AU  - Gallardo-Sánchez, Francisco
AU  - Pallarés-Manrique, Héctor
AU  - Gómez-García, María
AU  - Cabello-Tapia, María José
AU  - Talavera-Fabuel, Aurora
AU  - Bejarano-García, Ana
AU  - Leo-Carnerero, Eduardo
AU  - Hernández-Martínez, Álvaro
AU  - Caunedo-Álvarez, Ángel
AU  - Herrerías-Gutiérrez, Juan Manuel
PY  - 2016
DO  - 10.17235/reed.2016.4068/2015
SN  - 1130-0108
UR  - http://hdl.handle.net/10668/9747
T2  - Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
AB  - Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis. To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice. Retrospective study of the effectiveness and...
LA  - en
KW  - Adolescent
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - Colitis, Ulcerative
KW  - Female
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Injections, Subcutaneous
KW  - Male
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Treatment Outcome
KW  - Tumor Necrosis Factor-alpha
KW  - Young Adult
TI  - Initial experience with golimumab in clinical practice for ulcerative colitis.
TY  - research article
VL  - 108
ER  -